Key facts
- Valink Therapeutics’s last known valuation is $12.6M (Nov 2023).
- It has raised $20.5M across 1 recorded rounds; the latest was Seed Round ($7.6M) in Nov 2023.
- Notable investors include Y Combinator, Creative Destruction Lab, Metaplanet Holdings, Acequia Capital, University of Oxford — 18 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Valink Therapeutics
Funding rounds
1 roundsAbout Valink Therapeutics
Developer of a modular protein platform designed to facilitate the scalable discovery of bi-specific biologics. The company's platform uses robotic screening and big data analysis to discover bispecific lead assets with new modes of action to construct complex bispecific and multispecific biologics and deploys a scalable pipeline for internal and collaborative discovery of bispecific antibodies, from protein design to robotic screening and AI analysis, enabling medical practitioners to provide new alternatives to cancer treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 16
- Website
- valinktx.com/
- Ownership
- Privately Held (backing)
Valink Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valink Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valink Therapeutics in its N-PORT filings yet. We sweep new filings monthly.